Sort by
Refine Your Search
-
Listed
-
Country
-
Program
-
Field
-
About the German Cancer Research Center (DKFZ) The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute and a member of the Helmholtz Association of German Research Centers . Over 3,200 staff members from 88 nations are...
-
of protective responses for infectious diseases, particularly COVID-19 and influenza. The role involves the application of state-of-the-art software development methods, machine learning, and AI techniques
-
. UKF jobticket UKF Your challenges: develop and optimize high-throughput analysis pipelines integrate complex RNAseq, Whole Exome Sequencing and TCR repertoire high-throughput data apply machine learning
-
of the second year after a trainee joins the team. Job Duties Designs and implements novel computational algorithms for data analysis, feature extraction, and predictive modeling. Applies machine learning
-
of protective responses for infectious diseases, particularly COVID-19 and influenza. The role involves the application of state-of-the-art software development methods, machine learning, and AI techniques
-
to application of machine learning and data mining techniques to analyze multiple data modalities related to corneal disease, including imaging, genetic and clinical data. Qualifications PhD in Computer Science
-
into the cancer genome and epigenome using long-read sequencing and machine learning Gaining novel insights into the cancer genome and epigenome. This project will generate and analyse nanopore long-read sequencing
-
Climate Science, Hydrology, Environmental Science, or a related field. Experience in machine learning or AI applications in hydro-climate studies. Strong background with GIS tools and spatial analysis
-
approaches such as transcriptomics, proteomics, CyTOF and metabolomics. Developing cloud computational infrastructure, integrating multi-omics datasets and applying machine learning methods to high dimensional
-
investigator-initiated clinical trials. The cellular therapeutics will include but not limited to Chimeric Antigen Receptor (CAR) T-cells, Natural Killer (NK) cells and Hematopoietic stem and progenitor cells